OPKO Health (OPK) Competitors $1.51 -0.05 (-3.21%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.52 +0.01 (+0.66%) As of 10/10/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OPK vs. LGND, FOLD, CLDX, MNKD, NVAX, BCRX, DVAX, INVA, ZBIO, and GERNShould you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), Innoviva (INVA), Zenas BioPharma (ZBIO), and Geron (GERN). These companies are all part of the "biotechnology" industry. OPKO Health vs. Its Competitors Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics MannKind Novavax BioCryst Pharmaceuticals Dynavax Technologies Innoviva Zenas BioPharma Geron OPKO Health (NASDAQ:OPK) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability. Do institutionals & insiders believe in OPK or LGND? 64.6% of OPKO Health shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 49.7% of OPKO Health shares are held by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is OPK or LGND more profitable? OPKO Health has a net margin of -26.68% compared to Ligand Pharmaceuticals' net margin of -40.44%. Ligand Pharmaceuticals' return on equity of -9.21% beat OPKO Health's return on equity.Company Net Margins Return on Equity Return on Assets OPKO Health-26.68% -13.17% -8.28% Ligand Pharmaceuticals -40.44%-9.21%-8.09% Which has stronger valuation and earnings, OPK or LGND? Ligand Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOPKO Health$713.10M1.68-$53.22M-$0.25-6.04Ligand Pharmaceuticals$167.13M20.84-$4.03M-$4.00-44.43 Does the media prefer OPK or LGND? In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than OPKO Health. MarketBeat recorded 8 mentions for Ligand Pharmaceuticals and 4 mentions for OPKO Health. OPKO Health's average media sentiment score of 1.07 beat Ligand Pharmaceuticals' score of 0.78 indicating that OPKO Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate OPK or LGND? OPKO Health currently has a consensus price target of $2.63, suggesting a potential upside of 73.84%. Ligand Pharmaceuticals has a consensus price target of $176.50, suggesting a potential downside of 0.69%. Given OPKO Health's higher possible upside, analysts plainly believe OPKO Health is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OPKO Health 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Ligand Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has more volatility & risk, OPK or LGND? OPKO Health has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. SummaryOPKO Health beats Ligand Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get OPKO Health News Delivered to You Automatically Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPK vs. The Competition Export to ExcelMetricOPKO HealthMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.24B$7.00B$6.10B$10.63BDividend YieldN/A1.16%5.67%4.71%P/E Ratio-6.0426.2985.2726.57Price / Sales1.68192.73612.78132.63Price / Cash22.6822.0238.5062.09Price / Book0.765.1112.726.53Net Income-$53.22M$178.04M$3.30B$275.96M7 Day Performance-3.21%-2.10%0.94%-0.73%1 Month Performance5.59%5.62%6.34%3.71%1 Year Performance3.42%23.63%80.41%37.30% OPKO Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPKOPKO Health4.2813 of 5 stars$1.51-3.2%$2.63+73.8%+2.7%$1.24B$713.10M-6.042,997Analyst ForecastLGNDLigand Pharmaceuticals3.8983 of 5 stars$182.61+0.9%$176.50-3.3%+77.2%$3.58B$187.58M-45.6580News CoverageAnalyst ForecastFOLDAmicus Therapeutics4.4891 of 5 stars$8.16-0.5%$15.78+93.4%-17.4%$2.52B$571.16M-67.99480Analyst ForecastAnalyst RevisionCLDXCelldex Therapeutics2.2314 of 5 stars$26.38-0.1%$46.13+74.8%-9.8%$1.75B$7.02M-8.76150Analyst ForecastMNKDMannKind4.0102 of 5 stars$5.66-1.7%$11.17+97.3%-22.8%$1.74B$285.50M51.46400News CoverageAnalyst ForecastNVAXNovavax4.232 of 5 stars$9.08-4.0%$14.29+57.3%-35.5%$1.47B$1.08B3.981,990Analyst ForecastBCRXBioCryst Pharmaceuticals4.05 of 5 stars$7.02-1.8%$16.30+132.2%+1.4%$1.47B$557.51M-39.00530Analyst ForecastDVAXDynavax Technologies4.474 of 5 stars$10.14+0.4%$24.33+140.0%-3.1%$1.19B$316.27M-22.04350Analyst ForecastINVAInnoviva4.7656 of 5 stars$17.42-0.3%$37.60+115.8%-11.0%$1.10B$358.71M56.20100Analyst ForecastZBIOZenas BioPharma2.44 of 5 stars$23.03+5.8%$36.67+59.2%N/A$969.79M$5M-6.49N/ATrending NewsAnalyst ForecastInsider TradeGap UpGERNGeron2.6622 of 5 stars$1.28-5.2%$3.79+195.8%-69.7%$816.66M$164.45M-9.8570News CoverageAnalyst Forecast Related Companies and Tools Related Companies LGND Competitors FOLD Competitors CLDX Competitors MNKD Competitors NVAX Competitors BCRX Competitors DVAX Competitors INVA Competitors ZBIO Competitors GERN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPK) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OPKO Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OPKO Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
